VIPER-101 clinical trial is actively recruiting patients.
Organizations Involved
University of Pennsylvania
Company Description
Vittoria Biotherapeutics, Inc. is a clinical-stage immunotherapy company specializing in the development of innovative cell therapies for hard-to-treat diseases. The company’s proprietary Senza5 platform technology enhances T cell effector function through gene editing, with a focus on oncology and autoimmune diseases.
Market
Oncology
Location
Philadelphia,
Pennsylvania,
United States
Coinvestors
Valley Forge Investment Corporation, Global BioAccess Fund, Hatch Biofund, Agent Capital, Tellus BioVentures, NYBC Ventures, University of Pennsylvania